We are live on ! Find out more
FCM

Farallon Capital Management Portfolio holdings

AUM $17.5B
1-Year Est. Return 50.95%
This Fund
S&P 500
This Quarter Est. Return
+19.41%
1 Year Est. Return
+50.95%
3 Year Est. Return
+148.38%
5 Year Est. Return
+206.05%
10 Year Est. Return
+1,475.31%
AUM
$16.6B
AUM Growth
+$2.17B
Cap. Flow
-$81M
Cap. Flow %
-0.49%
Top 10 Hldgs %
31.47%
Holding
166
New
39
Increased
28
Reduced
33
Closed
30

Top Buys

Rank Stock Value
1
ARMK icon
Aramark
ARMK
+$366M
2
XLNX
Xilinx Inc
XLNX
+$332M
3
RTX icon
RTX Corp
RTX
+$299M
4
ALXN
Alexion Pharmaceuticals
ALXN
+$289M
5
AVGO icon
Broadcom
AVGO
+$243M

Top Sells

Rank Stock Value
1
IMMU
Immunomedics Inc
IMMU
+$498M
2
INFO
IHS Markit Ltd. Common Shares
INFO
+$299M
3
ABBV icon
AbbVie
ABBV
+$298M
4
PANW icon
Palo Alto Networks
PANW
+$217M
5
BMY icon
Bristol-Myers Squibb
BMY
+$215M

Sector Composition

Rank Sector Weight
1 Healthcare 38.27%
2 Communication Services 13.23%
3 Financials 10.05%
4 Technology 9.85%
5 Industrials 8.49%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
SURF
101
DELISTED
Surface Oncology, Inc. Common Stock
SURF
$9.24M 0.06%
+1,000,000
New +$8.69M
ACIA
102
DELISTED
Acacia Communications Inc
ACIA
$7.3M 0.04%
100,000
+40,000
+67% +$2.77M
FPRX
103
DELISTED
Five Prime Therapeutics, Inc.
FPRX
$6.8M 0.04%
+400,000
New +$5.01M
COGT icon
104
Cogent Biosciences
COGT
$7.24B
$6.74M 0.04%
+600,000
New +$6.59M
IMGN
105
DELISTED
Immunogen Inc
IMGN
$6.45M 0.04%
+1,000,000
New +$5.83M
MRVL icon
106
CALL
Marvell Technology
MRVL
$196B
$5.94M 0.04%
+125,000
New +$5.41M
CRIS icon
107
Curis
CRIS
$7.83M
$5.94M 0.04%
+1,813
New +$2.18M
STTK icon
108
Shattuck Labs
STTK
$694M
$5.24M 0.03%
+100,000
New +$3.21M
ISEE
109
DELISTED
IVERIC bio, Inc. Common Stock
ISEE
$5.21M 0.03%
754,740
– –
TGTX icon
110
TG Therapeutics
TGTX
$7.62B
$5.2M 0.03%
+100,000
New +$3.38M
ARWR icon
111
Arrowhead Research
ARWR
$12.4B
$5.19M 0.03%
67,600
-356,000
-84% -$22.8M
SVRA icon
112
Savara
SVRA
$1.19B
$5.12M 0.03%
4,452,086
– –
HMCOU
113
DELISTED
HumanCo Acquisition Corp. Unit
HMCOU
$4.41M 0.03%
+400,000
New +$4.44M
MASS icon
114
908 Devices
MASS
$364M
$4.27M 0.03%
+75,000
New +$4.38M
FDMT icon
115
4D Molecular Therapeutics
FDMT
$562M
$4.14M 0.02%
+100,000
New +$4.13M
KURA icon
116
Kura Oncology
KURA
$850M
$4.08M 0.02%
+125,000
New +$4.39M
EQ icon
117
Equillium
EQ
$133M
$3.75M 0.02%
700,000
– –
ALPN
118
DELISTED
Alpine Immune Sciences Inc
ALPN
$2.52M 0.02%
200,000
-541,290
-73% -$5.31M
IVA
119
Inventiva
IVA
$1.13B
$2.32M 0.01%
160,000
-367,870
-70% -$4.77M
SPRY icon
120
ARS Pharmaceuticals
SPRY
$612M
$2.21M 0.01%
+47,620
New +$1.59M
BRMK.WS
121
DELISTED
Broadmark Realty Capital Inc. Warrants, each exercisable for one fourth (1/4th) share of Common Stock at an exercise price of $2.875 per quarter share
BRMK.WS
$1.94M 0.01%
7,174,613
– –
GOL
122
DELISTED
Gol Linhas Aéreas Inteligentes S.A. American Depositary Shares (Each representing Ten Preferred Shares)
GOL
$843K 0.01%
85,838
– –
CEREW
123
DELISTED
Cerevel Therapeutics Holdings, Inc. Warrant
CEREW
$758K ﹤0.01%
+134,175
New +$541K
ADAP
124
DELISTED
Adaptimmune Therapeutics
ADAP
– –
-2,515,762
Closed -$20.1M
AMWL icon
125
American Well
AMWL
$230M
– –
-2,250
Closed -$1.33M
3 4
5
6 7

Similar funds

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
MCM
MAI Capital Management Independence, Ohio $17.7B AUM 18.87% 1-Year Est. Return
LA
Linden Advisors New York $17.9B AUM 1.72% 1-Year Est. Return
CM
Caption Management Oklahoma City, Oklahoma $17.1B AUM 70.99% 1-Year Est. Return
ASRS
Arizona State Retirement System Phoenix, Arizona $17.1B AUM 30.52% 1-Year Est. Return
PP
Prudential plc London, England, United Kingdom $17.1B AUM 15.7% 1-Year Est. Return
VMPIC
Varma Mutual Pension Insurance Co Helsinki, Finland $17B AUM 24.09% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

Farallon Capital Management's Q4 2020 Portfolio in Review

As of Q4 2020, Farallon Capital Management held 166 positions worth $16.6B, up 15% from $14.5B the previous quarter. Its ten largest holdings account for 31% of the portfolio.

Farallon Capital Management's Q4 2020 filing shows 39 new, 28 increased, 33 reduced and 30 closed positions. Its largest new stake was Aramark: 15,268,169 shares worth $424M. The largest sale was Immunomedics Inc, an estimated $498M.

By sector, the portfolio is most concentrated in Healthcare at 38% of assets, down from 41% a quarter earlier, followed by Communication Services and Financials.

  • Farallon Capital Management's largest Q4 2020 buy was Aramark: 15,268,169 shares worth $424M.
  • Farallon Capital Management added most to Willis Towers Watson in Q4 2020, an estimated $188M increase.
  • Farallon Capital Management's biggest Q4 2020 reduction was AbbVie, cutting an estimated $298M.
  • Farallon Capital Management fully exited Immunomedics Inc in Q4 2020, selling an estimated $498M.
  • Farallon Capital Management's ten largest holdings make up 31% of its $16.6B portfolio in Q4 2020.
  • Farallon Capital Management opened 39 new positions and closed 30 in Q4 2020.
  • Farallon Capital Management's portfolio value rose 15% quarter-over-quarter to $16.6B.

Based on Farallon Capital Management's 13F filing for Q4 2020, filed 16 Feb 2021.